Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 2
2016 6
2017 1
2018 5
2019 7
2020 3
2021 5
2022 10
2023 10
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Results by year

Filters applied: . Clear all
Page 1
Non-specific irreversible 89Zr-mAb uptake in tumours: evidence from biopsy-proven target-negative tumours using 89Zr-immuno-PET.
Wijngaarden JE, Jauw YWS, Zwezerijnen GJC, de Wit-van der Veen BJ, Vugts DJ, Zijlstra JM, van Dongen GAMS, Boellaard R, Menke-van der Houven van Oordt CW, Huisman MC. Wijngaarden JE, et al. Among authors: menke van der houven van oordt cw. EJNMMI Res. 2024 Feb 15;14(1):18. doi: 10.1186/s13550-024-01079-5. EJNMMI Res. 2024. PMID: 38358425 Free PMC article.
How to obtain the image-derived blood concentration from 89Zr-immuno-PET scans.
Wijngaarden JE, Ahbari A, Pouw JEE, Greuter HNJM, Bahce I, Zwezerijnen GJC, Vugts DJ, van Dongen GAMS, Boellaard R, Menke-van der Houven van Oordt CW, Huisman MC. Wijngaarden JE, et al. Among authors: menke van der houven van oordt cw. EJNMMI Phys. 2024 Feb 7;11(1):16. doi: 10.1186/s40658-024-00621-7. EJNMMI Phys. 2024. PMID: 38321232 Free PMC article.
First exploration of the on-treatment changes in tumor and organ uptake of a radiolabeled anti PD-L1 antibody during chemoradiotherapy in patients with non-small cell lung cancer using whole body PET.
Pouw JEE, Hashemi SMS, Huisman MC, Wijngaarden JE, Slebe M, Oprea-Lager DE, Zwezerijnen GJC, Vugts D, Ulas EB, de Gruijl TD, Radonic T, Senan S, Menke-van der Houven van Oordt CW, Bahce I. Pouw JEE, et al. Among authors: menke van der houven van oordt cw. J Immunother Cancer. 2024 Feb 1;12(2):e007659. doi: 10.1136/jitc-2023-007659. J Immunother Cancer. 2024. PMID: 38302416 Free PMC article.
Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial).
Mileva M, de Vries EGE, Guiot T, Wimana Z, Deleu AL, Schröder CP, Lefebvre Y, Paesmans M, Stroobants S, Huizing M, Aftimos P, Tol J, Van der Graaf WTA, Oyen WJG, Vugts DJ, Menke-van der Houven van Oordt CW, Brouwers AH, Piccart-Gebhart M, Flamen P, Gebhart G. Mileva M, et al. Among authors: menke van der houven van oordt cw. NPJ Breast Cancer. 2024 Jan 6;10(1):4. doi: 10.1038/s41523-023-00610-6. NPJ Breast Cancer. 2024. PMID: 38184611 Free PMC article.
89Zr-Immuno-PET with Immune Checkpoint Inhibitors: Measuring Target Engagement in Healthy Organs.
Miedema IHC, Wijngaarden JE, Pouw JEE, Zwezerijnen GJC, Sebus HJ, Smit E, de Langen AJ, Bahce I, Thiele A, Vugts DJ, Boellaard R, Huisman MC, Menke-van der Houven van Oordt CW. Miedema IHC, et al. Among authors: menke van der houven van oordt cw. Cancers (Basel). 2023 Nov 23;15(23):5546. doi: 10.3390/cancers15235546. Cancers (Basel). 2023. PMID: 38067257 Free PMC article.
Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial.
Wildiers H, Armstrong A, Cuypere E, Dalenc F, Dirix L, Chan S, Marme F, Schröder CP, Huober J, Duhoux FP, Vuylsteke P, Jager A, Brain E, Kuemmel S, Pápai Z, Menke-van der Houven van Oordt CW, Perjesi L, Mueller C, Brignone C, Triebel F. Wildiers H, et al. Clin Cancer Res. 2024 Feb 1;30(3):532-541. doi: 10.1158/1078-0432.CCR-23-1173. Clin Cancer Res. 2024. PMID: 37939105 Free PMC article. Clinical Trial.
Prediction of pathologic complete response after single-dose MR-guided partial breast irradiation in low-risk breast cancer patients: the ABLATIVE-2 trial-a study protocol.
Civil YA, Oei AL, Duvivier KM, Bijker N, Meijnen P, Donkers L, Verheijen S, van Kesteren Z, Palacios MA, Schijf LJ, Barbé E, Konings IRHM, -van der Houven van Oordt CWM, Westhoff PG, Meijer HJM, Diepenhorst GMP, Thijssen V, Mouliere F, Slotman BJ, van der Velde S, van den Bongard HJGD. Civil YA, et al. Among authors: van der houven van oordt cwm. BMC Cancer. 2023 May 9;23(1):419. doi: 10.1186/s12885-023-10910-6. BMC Cancer. 2023. PMID: 37161377 Free PMC article.
52 results